Immunohistochemistry shows high accuracy for BRAFV600E mutation in lung adenocarcinoma, indicating a reliable screening tool for personalized therapy.
Immunohistochemistry using VE1 antibody is a reliable and accessible initial screening tool for BRAFV600E mutation in lung adenocarcinoma. Strong, homogeneous cytoplasmic staining predicts mutation status with high accuracy, while weak or heterogeneous staining requires confirmatory molecular testing. The present findings provide essential local epidemiological data and support universal IHC testing to guide personalized therapy in NSCLC.
No takes yet. Share an insight, caveat, or question.
Čampar et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: